2018 has been a busy year for the molecular department. Two new assays have been added to our molecular test menu; APTIMA HSV 1 & 2 and the BD AFFIRM VAGINITIS PANEL.
The Aptima HSV 1 & 2 assay is a fully automated, real time nucleic acid amplification test that will qualitatively detect and differentiate between HSV-1 and HSV-2. The assay is only for active anogenital skin lesions collected in the Aptima Multi test swab. The assay yields results in 2.7 hours after the start of testing as opposed to several days with traditional culture methods.
The BD Affirm Vaginitis Panel is available from a swab that tests for the presence of DNA from Trichomonas, Gardnerella bacteria and seven types of Candida. It does not differentiate the types of Candida but is a rapid test for the most common causes of vaginitis.
Tulsa Medical lab has also been validated for testing chlamydia and gonorrhea mRNA from urine samples utilizing the Aptima Combo 2 assay on the Hologic Panther system.
In addition to HPV testing with high risk genotyping for pap smears, the Aptima high risk HPV and the Aptima Genotyping assays are also available for anal pap samples.
Ask us about access to our new physician portal for Web-Based ordering and results access via the Sunquest Physician Portal powered by Atlas.
Clinicians and their designated office staff can access our web based reporting system not only for online results access, but can also place their orders for laboratory testing electronically and ease of requisition completion and printing.
To obtain your Access LogOn and or for more information regarding the portal, please contact Tanya Odle at (918) 712-5571 extension 200. If you already have access to our portal, you can access the portal via the link below.
Access Physician Portal
Tulsa Medical Lab/Atlas Informational PDF
In August of 2016, the Tulsa Medical Lab Molecular Department completed validation studies to apply the Hologic Aptima HPV Genotyping Assay to head and neck fine needle aspiration samples.
Head and neck cancer is the 6th most common cancer worldwide with over 550,000 new cases each year. 90% of head and neck cancers are squamous cell carcinoma.
Currently, 72% of the oropharyngeal squamous cell carcinomas in the United States are HPV-related. HPV 16 is responsible for 90 to 95% of those cancers. Experts agree that E6/E7 detection of mRNA transcripts is generally regarded as the gold standard for HPV detection.
The Aptima HPV Genotyping Assay targets the E6/E7 mRNA of HPV 16 and 18/45 which makes it a superlative choice for determining the presence of HPV 16 in fine needle aspiration samples.
The 5 year survival rate for patients with HPV positive squamous cell carcinoma is greater than 80% compared to 40% for patients with HPV negative head and meck squamous cell carcinoma.
For more information on this exciting and affordable test, please contact the molecular department at 918-281-6865.
The Cellient™ Automated Cell Block System is the first fully-automated cell blocking system built on ThinPrep® technology. It improves capture by maximizing cellularity even from small/scanty samples. It also improves presentation by maintaining crisp, clear cellular architectural detail with concentrations of cells within the block.
This system allows for review of cytology and cell block simultaneously. It improves consistency by being fully automated with minimal operator dependency, resulting in less cross-contamination risk along with consistently rapid processing time (45 minutes or less).